New member | GenSensor

26 January 2022

By 2024, forecasts indicate that 50% of the top 100 most prescribed drugs will be biologics, accounting for 32% of the overall pharmaceutical market. Therapeutic progress and patient access to new biotherapies now rely on bioproduction capacity and performance. 

GenSensor is committed to provide innovative in line biosensors to help researchers to develop new and efficient expression systems, efficiently manage scale up phase, and for pharma company, secure their large production. GenSensor was founded with a vision to become a game changer in the field of genomic based in-line bioproduction monitoring.

This company combines the development of a robotic device with an advanced analytics software to monitor, characterize, optimize your bioproduction of ATMP and vaccines.

Find out more about GenSensor: